ArticleDigestive diseases and sciences2026
CKAP5: Unraveling Its Crucial Function in Liver Hepatocellular Carcinoma Progression and Prognosis.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Severe Acute Pancreatitis-Associated Lung Injury: A Comprehensive Quadruple Analysis of Animal Models.Digestive diseases and sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLiver hepatocellular carcinoma (LIHC) remains a leading cause of cancer-related mortality worldwide, with limited therapeutic options for advanced stages. Cytoskeleton-associated protein 5 (CKAP5), a key regulator of microtubule dynamics, has emerged as a potential oncogene in multiple cancers, yet its precise role and clinical relevance in LIHC pathogenesis and tumor immunity are not fully understood.
methodsWe systematically evaluated CKAP5 expression patterns using multi-omics data from TCGA, GEO, and the Human Protein Atlas. Prognostic significance was assessed through Kaplan-Meier survival analysis, Cox regression, and ROC curves. The association between CKAP5 and the tumor immune microenvironment was investigated via immune cell infiltration analysis, immune checkpoint correlation, and single-cell RNA sequencing. Mechanistic insights were explored through gene set enrichment analysis (GSEA), transcription factor activity inference, and protein-protein interaction network construction. Functional validation was performed using CRISPR-Cas9-mediated CKAP5 knockdown in HepG2 cells, followed by comprehensive assays measuring proliferation, migration, and invasion capabilities.
resultsCKAP5 was significantly overexpressed in LIHC tissues at both mRNA and protein levels, and its elevated expression correlated strongly with advanced tumor stage, poor differentiation, and unfavorable patient survival. CKAP5 expression was associated with distinct immune cell infiltration patterns and positively correlated with key immune checkpoint molecules (PD1, PDL1, and CTLA4). Bioinformatic analyses further revealed a potential mechanistic link between CKAP5 and immunosuppressive signaling pathways, including JAK-STAT and NF-κB. Functional studies demonstrated that CKAP5 depletion markedly suppressed LIHC cell proliferation, colony formation, migration, and invasion.
conclusionsOur integrated analysis establishes CKAP5 as a critical promoter of LIHC progression and a modulator of the tumor immune microenvironment. These findings nominate CKAP5 as a promising prognostic biomarker and a potential therapeutic target, providing new insights into LIHC pathogenesis and future treatment strategies.
Indexed as
Identifiers
41432972What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.